94 Histopathological response on clinicoradiological presentation and prognosis of patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy

Objectives To analyze the influence of histopathological response on clinicoradiological and survival of patients with high-grade serous ovarian carcinoma (HGSC) after neoadjuvant chemotherapy. Methods From 2008 to 2016, patients with advanced HGSC (FIGO IIIC-IVB) who underwent 6 cycles of NACHT (carboplatin-paclitaxel) followed by cytoreductive surgery were reviewed and divided in 3 groups: complete pathological response (1), pathological residual tumor with complete cytoreduction (2), and sub-optimal cytoreduction (3). CA-125 and computed tomography response were classified by RECIST criteria and compared using Fisher’s exact and McNemar tests, respectively. Progression-free survival (PFS) and overall survival (OS) were analyzed using Cox-proportional hazard. Results One-hundred-one patients, median age 60 years, followed by median of 36 months, were included. Groups 1 (n=10), 2 (n=61), and 3 (n=31) presented, respectively, mean OS of 75.7 (63–88); 55 (95% CI 41–69), and 26 (95% CI 19–32) months (p = Conclusions Complete histopathological response, normalization of CA-125 and complete radiological response after NACHT were associated with improved overall and disease free survival.